Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)
US9677139B2 · kind B2 · utility
3Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2012 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Jun 7, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.